Elixira:
The Licensing Roadmap for Global Deployment

From Cancer Prevention to Global Implementation
– The Ethical Blueprint for Licensing Elixira

Author: Tess Fries
Affiliation: Inventor and Founder of Elixira; Founder of Nanoism
Contact: contact@elixira.tech
Date: September 2025
DOI: https://doi.org/10.5281/zenodo.17216261

Abstract

Invented and founded by Tess Fries in 2025, Elixira is a breakthrough patent-pending AI-guided nanomedicine platform designed for autonomous, lifelong cancer prevention. Its feasibility has been independently documented by a leading Contract Research Organization (CRO), and all underlying technologies are scientifically validated. Elixira embodies the world's first form of preventive nanomedicine, inaugurating a new medical field called Nanoism, which signifies the convergence of nanotechnology, artificial intelligence, and autonomous energy systems into a self-sustaining paradigm of lifelong, proactive disease prevention.

This paper provides the first comprehensive blueprint for licensing Elixira, defining how preventive nanomedicine can be responsibly deployed worldwide. The framework balances exclusivity and collaboration, integrates diverse deployment pathways, and emphasizes ethical, equitable access. By establishing a transparent roadmap, Elixira's licensing model not only supports rapid implementation but also ensures sustainability, profitability, and global health equity. Remember, cancer will remain in the world until someone decides it won't.
Licensing is how we make it happen.

Keywords
Elixira, Nanoism, Licensing, Preventive Medicine, Global Deployment, Cancer Prevention, Nanobot, Biotechnology, Intellectual Property, Business Model, Healthcare, Healthcare Access, Innovation, Technology Transfer, Collaboration Models, Medtech, Deeptech, Nanomedicine, Life Science, Nanotechnology, AI-Guided Nanotechnology, Autonomous Health Systems, Prior Art, Public Disclosure, Global Health Equity, Licensing Roadmap, Future of Medicine, Tess Fries

1. Introduction

1.1 Why Licensing Matters in Cancer Prevention

For Elixira, licensing represents the vital bridge between vision and realization. To bring the promise of cancer prevention into global practice, Elixira must transcend the boundaries of individual laboratories and nations, embedding itself within diverse regulatory landscapes, healthcare infrastructures, and economic systems. To safeguard Elixira's ethical commitment—to make cancer prevention freely accessible to all, consistent with its business model (see Fries, 2025, *Elixira: The business model – How cancer prevention is 11× more profitable than cancer treatment*)—and to preserve its future evolution toward successive iterations capable of preventing additional diseases through the same foundational platform, licensing must prevail over equity.

Above all else, Elixira is not for sale. That means, no equity, no buyout—To relinquish Elixira to sale would be to imperil all that it represents—the human right to lifelong disease prevention and to a dignified existence. Equity is therefore non-negotiable, for the integrity of this direction must be preserved at all costs.

To realize Elixira, a licensee is required who embodies ethical orientation and shares the vision that guides its purpose. With the right licensee, Elixira can fulfill its mission of making cancer prevention a universal reality to end cancer worldwide, while establishing a durable foundation and clear direction for Nanoism (preventive nanomedicine) in accordance with the fundamental human right to lifelong disease prevention.

History has shown that transformative medical innovations—such as vaccines, insulin, and antiretrovirals—achieved global impact only through structured dissemination frameworks. Licensing agreements ensured not only commercial success but also equitable access. Elixira stands at a similar juncture, requiring a licensing blueprint that balances profit incentives with the moral imperative of universal prevention.

This aligns with evidence that population-level preventive measures, when systematically implemented, are among the most cost-effective approaches to reducing disease burden (Chokshi & Farley, 2012).

2. Partner Criteria

To ensure that Elixira is developed and deployed responsibly in accordance with the ethical framework of its mission, licensees must demonstrate three essential qualities.

First, as the non-negotiable foundation of collaboration, licensees must demonstrate a clear commitment to Elixira's ethical and preventive vision—prioritizing universal access that is free to patients and equally available across borders, in low-income and high-income regions alike, above profit. Ethics and the universal right to lifelong health and a dignified life form the very foundation of Elixira.

Second, they must possess expertise in nanotechnology and oncology, ensuring the scientific and technical capacity to bring preventive nanomedicine into practice.

Third, they must have sufficient capital to initiate implementation, with the ability to expand resources as Elixira progresses.

Partners will not be excluded for lacking the full resources to implement Elixira globally from the outset, as the priority is to begin deployment and make Elixira available in the world, regardless of region. Therefore, the emphasis is placed not on immediate global financial capacity, but on ethical commitment, perseverance, and alignment with the mission's long-term goals.
Priority must be to deploy Elixira, whether regionally or globally.

3. Benefits for Licensees

Licensees who partner with Elixira will write both history and the future as the first to implement cancer prevention, undertaking a role that transcends traditional business opportunity to become pioneers in shaping the future of medicine—by leading the world's first preventive nanomedicine platform and saving the lives of millions. Entering a field that is at present almost entirely unoccupied, they lead the world's first true implementation of cancer prevention and help establish the inaugural platform for preventive nanomedicine. In doing so, they are not merely participants in a new market; they are the architects of one.

This leadership extends to the founding of a new medical discipline, Nanoism, which unites nanotechnology, artificial intelligence, and autonomous energy systems into a self-sustaining framework for lifelong disease prevention. This aligns with the broader paradigm of P4 medicine, which emphasizes predictive, personalized, preventive, and participatory approaches to cancer medicine (Hood & Friend, 2011). By aligning with Elixira, licensees gain not only access to a breakthrough technology but also the unique opportunity to guide the evolution of an entire medical field.

Such a position carries historical significance. Licensees will be remembered as those who helped usher healthcare into an ethical era—where access is governed by the principles of human rights and dignity rather than financial privilege, where prevention is prioritized over treatment, and where patients receive cancer prevention free of charge. Within this model, innovation and profitability are not in conflict but converge, ensuring that long-term revenues are intrinsically aligned with global equity, ethics, and universal accessibility.

The first ones to take this step will not only license a technology—they will lead humanity into a new era of ethical, preventive, and universally accessible healthcare, where ethics and fundamental right to lifelong health governs the access to healthcare above profit.

Health is not a commodity to be sold, but a universal right to be safeguarded.
No price in the world can ever define our right to care.

4. Licensing Model

The licensing model adopted is success-based, deliberately designed to maximize the likelihood of achieving global implementation of cancer prevention by optimizing the chance for success for Elixira while minimizing risk for the licensee.
Trust, transparency, equality, and shared success are key to building a strong foundation for collaboration. This establishes fairness between inventor and licensee in medical innovation.

For a lifesaving technology to reach humanity on a global scale, risk must not be borne disproportionately by those who step forward as licensees, but must be shared equally between inventor and licensee. The most just and compelling framework is therefore a success-based licensing model, wherein the rights to build and implement Elixira are not tied to a burdensome initial fee but entrusted to the proof of real-world achievement, combined with defined support for the continued development and stewardship of Elixira (with such support mechanisms structured to safeguard mission-driven continuity rather than profit extraction).

In this model, the inventor's conviction is made manifest: Elixira's value is not measured in promises, but in milestones fulfilled and in the tangible progress of cancer prevention itself. This success-based licensing model represents the most equitable licensing model for licensees, where risk is minimized and trust is fostered between inventor and partner.

It stands as evidence of the inventor's faith and priority in both the invention and its significance for humanity, ensuring that the incentive is driven by success and sustained development, not by financial compensation alone. This represents the most just and effective pathway to realizing a lifesaving technology on a global scale—where collaboration founded on trust and shared success with humanity take precedence, affirming its ethical foundation and guiding purpose above financial gain and self-interest. Elixira, as a lifesaving technology designed for universal accessibility, must never be used for profit in a manner that excludes people from access to care; this principle begins with the licensing model.

5. Risk Reduction for Licensees

To increase the likelihood of cancer prevention implementation, the licensing framework for Elixira is deliberately designed to minimize financial and operational risk for licensees while safeguarding the ethical integrity and development of the technology. The following mechanisms ensure that obligations are proportionate, transparent, and directly tied to demonstrable progress.

5.1 Success-Based Licensing Model

To ensure that licensees are not burdened with high upfront costs and to encourage collaboration, the Elixira licensing model is fundamentally success-driven. Instead, they provide fees necessary to drive Elixira forward in terms of protection and development.

5.2 Defined Milestones

The licensee's 'all-or-nothing' risk is eliminated by distributing compensation across specific, verifiable stages of development, with compensation linked to success-based milestones, affirming that compensation to the inventor is inseparable from proven achievement.

5.3 Exit Clause

To protect licensees, encourage collaboration, and place Elixira's mission above personal gain, an exit clause is included. Should Elixira, against expectation, and upon clear and demonstrable evidence, be proven incapable of functioning in practical application, the licensee may terminate the agreement without financial loss. This clause establishes a solid foundation of trust between inventor and licensee and provides a strong assurance of legitimacy and security for the licensee. It underscores that compensation to the inventor is strictly tied to Elixira's proven success rather than assumptions or intentions, making clear that transparency, security, and equality between inventor and licensee — as well as Elixira's mission and impact — always come before profit.

5.4 Sublicensing Possibility (under Defined Ethical Framework)

To strengthen and accelerate the chances of global implementation, licensees may pursue sublicensing within the boundaries of Elixira's ethical framework. This enables collaboration with additional partners to advance cancer prevention worldwide, distributing both responsibility and revenues while ensuring that Elixira's original mission is preserved.

5.5 Impact-Driven Royalty Framework

To protect the licensee, royalties are payable solely on revenues generated from actual sales of Elixira. If no sales occur, no royalties shall be due. This ensures that profit is secondary.
The mission of cancer prevention is primary — and that principle is embedded in every clause.

5.6 Stepwise or Global Territory Rights (Flexible by Capacity)

To maximize the potential for accelerating Elixira's global reach to the people, expansion rights are structured with flexibility to best suit each licensee's capacity. Licensing may begin within a limited territory, with expansion rights granted as success is demonstrated. Where a licensee has the proven capacity, resources, and ethical alignment to operate globally from the outset, global rights may be granted directly. This flexible framework ensures that Elixira's implementation is both safeguarded and accelerated, adapting to the partner's ability to deliver cancer prevention effectively. By allowing licensees to scale gradually rather than commit to global obligations at once, the framework increases the likelihood of widespread and sustainable cancer prevention.

5.7 Ethical Safeguards

All implementation is bound by strict ethical principles to protect both Elixira and the licensee from reputational, regulatory, and investor risks:

• No exploitation: Elixira must never be used for profit in a manner that excludes people from access to care. People must always come before profit.

• Fair models: Differentiated pricing ensures that low-income regions are never excluded.

• Medical ethics: No shortcuts in clinical trials; full transparency is always required.

• Communication: All representation of Elixira must align with its preventive and humanitarian mission — people over profit — and must avoid sensationalism.

By embedding ethics and equity into the framework, Elixira mitigates multiple forms of risk for both Elixira and licensees:

• Reputational risk: Elixira and licensees are protected from associations with unethical practices.

• Regulatory risk: Ethical safeguards facilitate smoother approval from global authorities.

• Investor risk: Venture funds, NGOs, and aligned capital are reassured by the technology's strong ethical foundation, making support more accessible.

5.8 Differentiated Pricing: Ethical Capacity-Driven Scalable Cost Model

To guarantee global accessibility to cancer prevention and accelerate worldwide implementation, Elixira adopts a differentiated pricing model designed to include every country, regardless of financial resources. Larger, capital-strong markets (e.g., USA, EU) may contribute more once implementation is successful, while smaller or lower-income markets operate with a lower threshold. This enhances stability for global implementation by increasing overall security for licensees and mitigating potential financial loss in low-income regions. Access to healthcare must never be determined by financial capacity. This demonstrates to licensees that the model is scalable, flexible, and ethically aligned, ensuring that no region is excluded from access to cancer prevention — as the people's right to lifelong cancer prevention is universal across all borders and must always include everyone and come before profit.

5.9 Technology Safeguards by Design

So that reliability, continuity, and ethical compliance govern across all stages of development and deployment, Elixira is equipped with integrated technological safeguards designed to minimize the risk of malfunction or failure. These safeguards provide licensees with an additional layer of assurance that Elixira's performance and integrity are protected by design.

6. License Duration

For the mission of Elixira to remain intact, the license shall take effect upon signature of the agreement and shall remain in force for as long as Elixira is actively developed and/or implemented to provide cancer prevention in accordance with its ethical framework. The license framework is built on the principle of continuous commitment, meaning that development and implementation will continue until Elixira has been fully realized in practice. Termination of the agreement shall only be considered valid in the event of a material breach of the agreement or upon clear and verifiable evidence that Elixira cannot be implemented. Ongoing support fees required for commitment, development, stewardship, milestones, and IP protection remain applicable as defined. In addition, the license fee becomes payable upon successful implementation of Elixira. All performance-related financial compensation beyond these defined fees is strictly tied to revenues, ensuring that no sales mean no royalties from the licensee to the inventor. This structure guarantees both continuity of access for people and protection for the licensee, while safeguarding ethical stewardship beyond the lifespan of patents.

7. Licensing Fees

Elixira's licensing model is success-based and designed with the priority of maximizing the chance of global implementation of cancer prevention while safeguarding Elixira itself.
It achieves this by minimizing financial risk for licensees to encourage collaboration, while requiring certain fees to demonstrate commitment and to support the ongoing development and stewardship of Elixira.

7.1 Elixira Development Support Fee

This fee is intended as a one-time support mechanism to strengthen the inventor's capacity to focus fully on the continued development, ethical stewardship, and global implementation of Elixira by providing the necessary economic foundation. It protects the inventor from financial strain and supports the ability to drive Elixira forward. It ensures that the technology advances without compromise of resources and remains firmly aligned with its preventive and humanitarian mission.

7.2 Honorary Commitment Fee

To serve as evidence of genuine engagement and responsibility towards Elixira, licensees are required to provide an Honorary Commitment Fee as a credible initial support mechanism. This acts as a filter to ensure that only serious partners enter the framework, safeguarding the integrity of the technology, establishing mutual accountability between inventor and licensee from the outset, and standing as clear proof of commitment and seriousness.

7.3 Ethical IP Protection Fee

To protect and ensure ethical control and development of Elixira, IP protection is vital and must be covered by the licensees. This fee will go directly towards securing and maintaining intellectual property protection in the territory in which the licensees are licensed to implement Elixira. It includes all costs related to patents, trademarks, and associated filings, renewals, and enforcement, thereby ensuring both local enforceability and shared responsibility for the ethical safeguarding of Elixira worldwide.

7.4 Success-based Milestone Payments

For focus to remain on the development of Elixira before profit to the inventor, as well as minimizing risk to the licensee, compensation is structured as milestone payments that are released only by verifiable progress. Milestones may include, but are not limited to, the following illustrative stages:

- Proof-of-concept validated by a CRO
- Regulatory approval for clinical trials
- First successful clinical studies
- Regulatory approval by FDA, EMA, or WHO
- First implementation in healthcare systems → Activation of the licensing fee and royalties.

7.5 Impact-Driven Royalty Framework

To ensure that profit is always secondary to mission, royalties are impact-driven and payable only on revenues generated from actual sales of Elixira. In honor of the licensee's bold step toward global health, financial obligations shall not arise if Elixira cannot reach the public. Therefore, in fairness and recognition of the licensee's commitment, if no sales occur, no royalties shall be due. This structure guarantees that financial compensation remains inseparable from real-world implementation and measurable impact, ensuring that cancer prevention for people always comes before profit for the inventor.

7.6 Sublicensing Revenue Share

In order to guarantee that value created through sublicensing flows back to support Elixira's mission and strengthen the platform's potential for future expansion into the prevention of other diseases, the inventor shall, upon sublicensing, be entitled to a share of any revenues generated from such sublicensing agreements, in addition to milestone payments, the licensing fee upon implementation, and royalties only from direct sales.

8. Deployment Pathways

So that Elixira receives regulatory approval as quickly and safely as possible—allowing cancer prevention to reach the public without delay—the deployment framework integrates global regulatory alignment, scalable clinical development, and decentralized manufacturing.

8.1 Clinical and Regulatory Alignment

As part of securing rapid yet safe global implementation, licensees will collaborate with contract research and manufacturing organizations (CROs/CDMOs) for clinical development and scale-up. Regulatory submissions will be aligned with FDA, EMA, and WHO prequalification pathways, thereby facilitating efficient cross-border adoption and harmonized international approval.

8.2 Manufacturing and Distribution

To ensure resilient and uninterrupted access to preventive nanomedicine after production, Elixira will not rely on a single central facility. Instead, decentralized production hubs will be established across different regions of the world, reducing dependency on any one supply chain and safeguarding continuity of cancer prevention delivery.

Together, these pathways establish a resilient foundation for Elixira's worldwide deployment, ensuring that cancer prevention is delivered efficiently, ethically, and without interruption.

9. Collaboration Models

To successfully implement Elixira on a global scale, licensees are responsible for establishing and maintaining the partnerships required to ensure ethical, effective, and widespread deployment. The following collaboration models outline the primary domains where strategic alliances are essential.

9.1 Industry Partnerships

Pharmaceutical companies, biotech firms, and medtech innovators can collaborate through strategic alliances, ensuring faster regulatory approvals and wider market penetration.

9.2 Academic and NGO Collaborations

Universities and NGOs can access research sublicenses for continued development, ensuring scientific rigor and social responsibility.

9.3 Governmental Engagement

Governments are engaged primarily as regulators and adopters, but direct ownership is excluded to safeguard independence from political interference.

Together, these collaboration models establish the essential domains required for a balanced framework of global implementation. While other forms of partnerships may complement and accelerate deployment, these three domains remain foundational and therefore apply to all licensees, leaving flexibility in how each partnership beyond these is structured according to capacity and regional context.

10. Economic and Societal Impact

To ensure that cancer prevention is implemented on a global scale and made accessible to all people as a human right rather than a privilege, Elixira's licensing model establishes a sustainable revenue framework, enabling equitable global access through differentiated pricing and NGO collaboration, and aligns with key United Nations Sustainable Development Goals, particularly SDG 3 and SDG 10. Analyses further confirm that preventive care represents a high-value strategy for health systems, offering significant long-term returns both in economic and societal terms (Cohen, Neumann, & Weinstein, 2008).

The goal of SDG 3 means ensuring healthy lives and promoting well-being for all people at all ages through prevention, treatment, and universal access to healthcare.
The goal of SDG 10 means reducing inequalities within and among countries, ensuring equal access to resources and healthcare regardless of socioeconomic status.
This aligns with the World Health Organization's recommended 'best buys' for NCD prevention, which emphasize cost-effective, scalable interventions as essential for reducing global health inequities (World Health Organization, 2024).

10.1 Profitability and ROI

In order to secure long-term sustainability and measurable impact of cancer prevention implementation, licensing Elixira establishes a revenue model that surpasses traditional cancer treatment markets by focusing on prevention for the entire global population. Systematic reviews confirm that public health interventions consistently deliver strong returns on investment, further validating prevention as a sustainable economic strategy (Masters, Anwar, Collins, Cookson, & Capewell, 2017).

10.2 Equity and Global Access

So that cancer prevention is equally accessible across both low-income and high-income regions, Elixira adopts differentiated pricing models and collaborates with NGOs, transforming prevention into a birthright rather than a privilege.

10.3 Alignment with Global Goals

To contribute to the broader advancement of global health and equity, Elixira's licensing model aligns with multiple UN Sustainable Development Goals, particularly SDG 3 (Good Health and Well-Being) and SDG 10 (Reduced Inequalities).

Call To Action

Elixira has received rapidly growing global recognition and is now welcoming licensing opportunities with select partners in nanotechnology and oncology.

Elixira has already demonstrated exceptional early traction across multiple global platforms, underscoring both its scientific foundation and its emergence as a global movement. In September 2025, Elixira was ranked among the Top 5 Healthcare Companies and Startups in Lund by F6S, and simultaneously featured among the 34 leading Preventive Healthcare Companies and Startups worldwide. In parallel, Elixira has repeatedly trended globally on Crunchbase—first in Medical Device, then in Healthcare, and again in Medical Device—reflecting sustained and growing visibility in the international innovation ecosystem. The inventor and founder, Tess Fries, was further ranked among the Top 100 most prominent individuals worldwide (CB Rank #86) within Crunchbase's network of 2,060,548 entrepreneurs, investors, and innovators—achieving this position with Elixira as her sole venture, in contrast to others at this level who typically manage portfolios of 8–88 companies.

Elixira is being increasingly approached by nanotechnology experts, venture capital funds, and journalists, while on the academic front it has published a portfolio of peer-disseminated white papers amounting to more than 100 pages of documented work. Its first publication alone is approaching 1,000 downloads within a month according to the Zenodo API—an exceptional outcome for research released without conference, media, or institutional backing. With downloads continuing to grow daily, this provides clear evidence that Elixira has already achieved global attention. Elixira is moving fast.

The question is not *if* cancer prevention will be implemented globally, but *who* will lead the way.

Inquiries aligned with Elixira's ethical and preventive mission are prioritized:
licensing@elixira.tech

11. Conclusion

Elixira's licensing roadmap is more than a legal framework—it is a global health strategy.
By providing a structured, ethical, and economically sustainable pathway, licensing ensures that preventive nanomedicine can transcend borders. It allows Elixira to serve as both a technological and humanitarian breakthrough, shifting healthcare from treatment to prevention, from responding to illness to preserving health, and from privilege determined by wealth to a universal right from birth.

Entering into this agreement means not trying but deciding to prevail, and is not only a legal act but an ethical one—it signifies shouldering the weight of prevention for humanity together, and carrying the meaning it holds for the world when that day comes, without retreat in the face of external pressure.

As with all endeavors, challenges will arise—but that is all they are.
Challenges are meant to be overcome, and through our vision for mankind we face them together. It is through overcoming them that cancer prevention will reach humanity and one day free us from cancer.

Ethics is not optional but a necessity within the Elixira licensing model, and signifies a new pathway for healthcare—where technology, ethics, and human dignity converge.
Healthcare must be inseparably bound to ethics—for it lays the very foundation of the conditions that define what it means not just to exist—but to live.

Author’s Note

Dedicated to all lives touched by cancer, and to a future free from it.

The main goal of this licensing model has been to answer a single question:
“What can best maximize the chance of implementing cancer prevention into the world in a way that is best for the people?”

Everything within this framework is intended to uphold the universal right to health and to optimize the chance of eliminating cancer.

This licensing model is created to prevent cancer and to give voice to all who have been touched by it—whether they are with us today or tomorrow—and to restore our fundamental rights to lifelong health and a life free from cancer.

By sharing this blueprint openly, I invite collaborators, visionaries, and ethical partners worldwide to join in deploying Elixira.
The transition from cancer prevention to global implementation is not only possible, it is inevitable. I will end where I began, because some truths deserve repetition:

“*Remember, cancer will remain in the world until someone decides it won’t.*

Licensing is how we make it happen.”

References

Fries, T. (2025). *Elixira: The business model – How cancer prevention is 11× more profitable than cancer treatment*. Zenodo. https://doi.org/10.5281/zenodo.17082329

Chokshi, D. A., & Farley, T. A. (2012). The cost-effectiveness of environmental approaches to disease prevention. *New England Journal of Medicine, 367*(4), 295–297. https://doi.org/10.1056/NEJMp1206268

Cohen, J. T., Neumann, P. J., & Weinstein, M. C. (2008). Does preventive care save money? *New England Journal of Medicine, 358*(7), 661–663. https://doi.org/10.1056/NEJMp0708558

Hood, L., & Friend, S. H. (2011). Predictive, personalized, preventive, participatory (P4) cancer medicine. *Nature Reviews Clinical Oncology, 8*(3), 184–187. https://doi.org/10.1038/nrclinonc.2010.227

Masters, R., Anwar, E., Collins, B., Cookson, R., & Capewell, S. (2017). Return on investment of public health interventions: A systematic review. *Journal of Epidemiology & Community Health, 71*(8), 827–834. https://doi.org/10.1136/jech-2016-208141

World Health Organization. (2024). *Tackling NCDs: Best buys and other recommended interventions for the prevention and control of noncommunicable diseases* (2nd ed.). WHO. https://www.who.int/publications/i/item/9789240091078